Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 8, 2014 - Issue
Submit an article Journal homepage
1,049
Views
232
CrossRef citations to date
0
Altmetric
Review

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

Michael A NauckDepartment of Internal Medicine, Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, GermanyCorrespondence[email protected]
Page 1380 | Published online: 11 Sep 2014

Citations (232)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (23)

Lia Meuthia Zaini, Arief S Kartasasmita, Tjahjono D Gondhowiardjo, Maimun Syukri & Ronny Lesmana. (2022) Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy. Expert Review of Ophthalmology 17:3, pages 199-210.
Read now
Junyi Yang. (2018) Ertugliflozin for treatment of patients with Type 2 diabetes mellitus. Expert Review of Clinical Pharmacology 11:8, pages 747-753.
Read now
Liang Xu & Tsuguhito Ota. (2018) Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte 7:2, pages 121-128.
Read now
John Lally, Aonghus O’ Loughlin, Brendon Stubbs, Allys Guerandel, Donal O’Shea & Fiona Gaughran. (2018) Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. Expert Review of Clinical Pharmacology 11:4, pages 411-424.
Read now
Agostino Consoli, Gloria Formoso, Maria Pompea Antonia Baldassarre & Fabrizio Febo. (2018) A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opinion on Drug Safety 17:3, pages 293-302.
Read now
Hiroshige Mikamo, Yuka Yamagishi, Hiroyuki Sugiyama, Hisato Sadakata, Shun Miyazaki, Takako Sano & Tsutomu Tomita. (2018) High glucose-mediated overexpression of ICAM-1 in human vaginal epithelial cells increases adhesion of Candida albicans. Journal of Obstetrics and Gynaecology 38:2, pages 226-230.
Read now
Guntram Schernthaner, Sarah Jarvis, Chaim Lotan, Martin Prázný, Christoph Wanner & Thomas C Wascher. (2017) Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. Therapeutics and Clinical Risk Management 13, pages 69-79.
Read now
Sayf A Yassin & Vanita R Aroda. (2017) Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy 11, pages 923-937.
Read now
Ranjeet Prasad Dash, R. Jayachandra Babu & Nuggehally R. Srinivas. (2017) Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica 47:11, pages 1015-1026.
Read now
Paola Fioretto & Angelo Avogaro. (2017) Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 517-527.
Read now
Kelly F Bell, Arie Katz & John J Sheehan. (2016) Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies. Risk Management and Healthcare Policy 9, pages 231-241.
Read now
Melanie Davies, Sudesna Chatterjee & Kamlesh Khunti. (2016) The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications 8, pages 61-81.
Read now
Philip A Levin. (2016) Practical combination therapy based on pathophysiology of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 9, pages 355-369.
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2016) Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1367-1380.
Read now
K. Pafili, E. Maltezos & N. Papanas. (2016) The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. Expert Opinion on Investigational Drugs 25:10, pages 1133-1152.
Read now
Vishal Kothari, John A Galdo & Suresh T Mathews. (2016) Hypoglycemic agents and potential anti-inflammatory activity. Journal of Inflammation Research 9, pages 27-38.
Read now
Marie Helene Schernthaner-Reiter & Guntram Schernthaner. (2016) Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. Expert Review of Endocrinology & Metabolism 11:3, pages 281-296.
Read now
Jay H Shubrook, Babak Baradar Bokaie & Sarah E Adkins. (2015) Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy 9, pages 5793-5803.
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Anthony H. Barnett, Bernard Charbonnel, Robert G. Moses & Sanjay Kalra. (2015) Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 31:10, pages 1919-1931.
Read now
Robert M. Guthrie. (2015) Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgraduate Medicine 127:5, pages 463-479.
Read now
Maka S Hedrington & Stephen N Davis. (2015) Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:4, pages 613-623.
Read now
Marianna Maranghi, Anna Carnovale, Cosimo Durante, Giovanna Tarquini, Giusy Tiseo & Sebastiano Filetti. (2015) Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 125-137.
Read now

Articles from other publishers (209)

Yudan Zhao, Wanyue Yang, Xin Zhang, Chongning Lv & Jincai Lu. (2023) Icariin, the main prenylflavonoid of Epimedii Folium, ameliorated chronic kidney disease by modulating energy metabolism via AMPK activation. Journal of Ethnopharmacology 312, pages 116543.
Crossref
Tania Sundra, Erin Kelty & David Rendle. (2022) Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: A case series. Equine Veterinary Education 35:6, pages 311-320.
Crossref
Sensen Su, Zhanchuan Ma, Hao Wu, Zhonggao Xu & Huanfa Yi. (2023) Oxidative stress as a culprit in diabetic kidney disease. Life Sciences 322, pages 121661.
Crossref
Baptist Gallwitz. (2023) Diabetestherapie bei herzkranken Patienten. Diabetes aktuell 21:03, pages 123-132.
Crossref
Iwona Piątkowska-Chmiel, Mariola Herbet, Monika Gawrońska-Grzywacz, Kamil Pawłowski, Marta Ostrowska-Leśko & Jarosław Dudka. (2023) Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology 240:4, pages 983-1000.
Crossref
Xueting Yao, Jiawei Zhou, Ling Song, Yupeng Ren, Pei Hu & Dongyang Liu. (2023) A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors. CPT: Pharmacometrics & Systems Pharmacology 12:4, pages 487-499.
Crossref
Adnan Zaina, Nunzia Prencipe, Elena Golden, Alessandro Maria Berton, Eldad Arad, Ali Abid, Jeryes Shehadeh, Sameer Kassem & Ezio Ghigo. (2023) How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients. Endocrine 80:3, pages 491-499.
Crossref
Luxi Ji, Mudit Mishra & Bart De Geest. (2023) The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. Pharmaceutics 15:4, pages 1092.
Crossref
Soo Heon Kwak, Kyung Ah Han, Kyung‐Soo Kim, Jae Myung Yu, EunSook Kim, Jong Chul Won, Jun Goo Kang, Choon Hee Chung, Seungjoon Oh, Sung Hee Choi, Kyu Chang Won, Sin Gon Kim, Seung Ah Cho, Bo Young Cho & Kyong Soo Park. (2023) Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial . Diabetes, Obesity and Metabolism.
Crossref
Ece Guler, Ayse Nur Hazar-Yavuz, Esra Tatar, Mohammad Morid Haidari, Gul Sinemcan Ozcan, Gokhan Duruksu, Manuel Pedro F Graça, Deepak M Kalaskar, Oguzhan Gunduz & Muhammet Emin Cam. (2023) Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance. International Journal of Pharmaceutics 635, pages 122716.
Crossref
Jaime A Davidson, Norlela Sukor, Fen‐Lee Hew, Mafauzy Mohamed & Zanariah Hussein. (2022) Safety of sodium–glucose c otransporter  2 inhibitors in Asian type 2 diabetes populations . Journal of Diabetes Investigation 14:2, pages 167-182.
Crossref
Baptist Gallwitz. (2023) Diabetestherapie bei herzkranken Patienten. Diabetologie und Stoffwechsel 18:01, pages 44-56.
Crossref
Tatsuhiko Urakami, Kei Yoshida & Junichi Suzuki. (2023) Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes. Internal Medicine 62:2, pages 177-186.
Crossref
Shinichiro Shirabe, Katsuya Yamazaki, Mariko Oishi, Keiko Arai, Noriharu Yagi, Manaka Sato, Masakazu Takeuchi, Takahito Kai & Hiroshi Maegawa. (2022) Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70). Journal of Diabetes Investigation 14:1, pages 75-80.
Crossref
D. V Kurkin, E. I Morkovin, D. A Bakulin, Yu. V Gorbunova, A. V Strygin, A. I Robertus, I. E Makarenko, V. B Saparova, R. V Drai & V. I Petrov. (2022) MODERN CONCEPTS OF THE PATHOGENESIS OF TYPE 2 DIABETES MELLITUS. Journal of Volgograd State Medical University 19:4, pages 34-49.
Crossref
Jonali Ramani, Harshil Shah, Vivek K. Vyas & Manmohan Sharma. (2022) A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 6, pages 100074.
Crossref
Tara Ranjbar, Jennifer L. O’Connor & Khosrow Kashfi. 2022. The Role of Nitric Oxide in Type 2 Diabetes. The Role of Nitric Oxide in Type 2 Diabetes 210 237 .
Lei Tian, Sinan Ai, Huijuan zheng, Hanwen Yang, Mengqi Zhou, Jingyi Tang, Weijing Liu, Wenjing Zhao & Yaoxian Wang. (2022) Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Frontiers in Pharmacology 13.
Crossref
Paghunda Ehsan, Rawia N Aburumman, Shivani Ishwarya Muthanna, Swathi Radhakrishnan Menon, Vruti Vithani, Bansi Sutariya, Diana M Montenegro, Michael Chukwu & Sai Sri Penumetcha. (2022) Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?. Cureus.
Crossref
James E. Frampton. (2022) Empagliflozin: A Review in Symptomatic Chronic Heart Failure. Drugs 82:16, pages 1591-1602.
Crossref
Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, Donato Cappetta, Konrad Urbanek, Antonella De Angelis, Lucia Scisciola, Irene Di Meo, Maria Giuseppa Sullo, Concetta Rafaniello & Liberata Sportiello. (2022) Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Frontiers in Cardiovascular Medicine 9.
Crossref
Tania Sundra. (2022) Medical management of acute laminitis. UK-Vet Equine 6:5, pages 186-192.
Crossref
Wenyi Ma, Longgao Xiao, Haiyang Liu & Xiaojiang Hao. (2022) Hypoglycemic natural products with in vivo activities and their mechanisms: a review. Food Science and Human Wellness 11:5, pages 1087-1100.
Crossref
Yong-Yi Huang, Xiang-Kun Qin, Yuan-Yuan Dai, Liang Huang, Gan-Rong Huang, Yan-Chun Qin, Xian Wei & Yan-Qiang Huang. (2022) Preparation and hypoglycemic effects of chromium- and zinc-rich Acetobacter aceti . World Journal of Diabetes 13:6, pages 442-453.
Crossref
Adnan A. Zainal & Marwan M. Merkhan. (2022) IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW. Military Medical Science Letters 91:2, pages 140-160.
Crossref
Manar M. Elhassan, Amr M. Mahmoud, Maha A. Hegazy & Shereen Mowaka. (2022) Kinetic Degradation Study of Ipragliflozin Coupled with MS/MS Structural Elucidation. Chromatographia 85:3, pages 233-245.
Crossref
Lingxiang Xie, Yang Xiao, Shi Tai, Huijie Yang, Shenghua Zhou & Zhiguang Zhou. (2022) Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism. Frontiers in Pharmacology 13.
Crossref
Hyeri Yang, Eunmi Choi, Eunjun Park, Eonji Na, Soo Youn Chung, Bonggi Kim & Soon Young Han. (2022) Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. Pharmacology Research & Perspectives 10:1.
Crossref
Sangita Swapnasrita, Aurélie Carlier & Anita T. Layton. (2022) Sex-Specific Computational Models of Kidney Function in Patients With Diabetes. Frontiers in Physiology 13.
Crossref
Naomi Sugimoto, Yuka Yamagishi & Hiroshige Mikamo. (2022) Effect of Empagliflozin on <i>Candida glabrata</i> Adhesion to Vaginal Epithelial Cells. Medical Mycology Journal 63:2, pages 43-47.
Crossref
Ashley Meredith, Sydney Starks, Cassandra Etelamaki, Shelby Albertson, Jessica Triboletti, Lauren Pence, Todd Walroth, Kirsten McGrew & Jasmine Gonzalvo. (2021) Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor Use in an Underserved Ambulatory Care Population With Type 2 Diabetes. ADCES in Practice 10:1, pages 16-24.
Crossref
Dainis Kaldre. 2022. Comprehensive Heterocyclic Chemistry IV. Comprehensive Heterocyclic Chemistry IV 491 511 .
Derun Taner Ertugrul, Erdal Kan, Cigdem Bahadir Tura, Haci Bayram Tugtekin, Hayati Ayakta, Mehmet Celebioglu, Ceren Yılmaz, Onur Utebay, Ilhan Yetkin, Eren Gurkan, Kerem Sezer, Ramazan Gen, Suleyman Ozcaylak, Yildiz Okuturlar, Mehmet Coskun, Nilgun Govec Giynas, Harun Aysal, Ayca Serap Erdem, Mustafa Aydemir, Okan Bakiner, Emre Cicekli, Deniz Gezer, Ramazan Kaya, Levent Kebapcilar, Umit Cinkir, Memmune Sena Ulu, Canan Ersoy, Mustafa Timur Kagan, Berna Dalmis Ekiz, Faruk Kilinc, Kevser Onbasi, Mahir Cengiz, Mehmet Celik, Metin Guclu, Metin Sarıkaya, Ozcan Ozbag, Ramazan Sari, Rifki Ucler, Selcuk Sezikli, Mustafa Araz, Erdal Gundogan, Erhan Bozkurt, Murat Akbas, Rifat Bozkus, Baris Akinci, Ersen Karakilic, Murat Medeni, Ozgur Keskek, Enver Sukru Goncuoglu, Sayid Shafi Zuhur, Ahmet Ziya Sahin, Kursat Dal, Mehmet Ali Eren, Tugba Arkan, Bengur Taskiran, Gokturk Kilinc, Emre Bozkirli, Sabriye Ozkaya Kafesciler, Nuh Kafesciler, Esra Cil Sen, Sahin Doganay, Caglar Koseoglu, Tamer Tetiker, Taner Bayraktaroglu, Aytekin Oguz, Esra Ataoglu, Muhammed Mustafa Demirpence, Semra Tursun, Inan Anaforoglu, Omur Tabak, Rifat Emral, Kubilay Karsidag, Oguzhan Sitki Dizdar, Alparslan Kemal Tuzcu, Mustafa Caliskan, Pinar Sirmatel, Yasin Kocaoz, Hakan Dogan, Semin Melahat Fenkci, Ibrahim Sahin & Zuleyha Karaca. (2021) Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes. International Journal of Diabetes in Developing Countries 42:1, pages 147-160.
Crossref
Lina T. Al Kury, Aya Abdoh, Kamel Ikbariah, Bassem Sadek & Mohamed Mahgoub. (2021) In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update. Molecules 27:1, pages 182.
Crossref
Kohei Kaku, Takashi Kadowaki, Yutaka Seino, Taro Okamoto, Masayoshi Shirakawa, Asako Sato, Edward A. O'Neill, Samuel S. Engel & Keith D. Kaufman. (2021) Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, Obesity and Metabolism 23:9, pages 2099-2108.
Crossref
Rune E. Kuhre, Carolyn F. Deacon, Nicolai J. Wewer Albrechtsen & Jens J. Holst. (2021) Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?. Diabetes, Obesity and Metabolism 23:9, pages 2009-2019.
Crossref
Katharina Schütt, Martin Berger & Nikolaus Marx. (2021) SGLT-2 Inhibition – neues Therapiekonzept bei Herzinsuffizienz. Aktuelle Kardiologie 10:04, pages 297-301.
Crossref
Francisco Canet, Francesca Iannantuoni, Aránzazu Martínez de Marañon, Pedro Díaz-Pozo, Sandra López-Domènech, Teresa Vezza, Blanca Navarro, Eva Solá, Rosa Falcón, Celia Bañuls, Carlos Morillas, Milagros Rocha & Víctor M. Víctor. (2021) Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?. Antioxidants 10:8, pages 1228.
Crossref
Leszek Szablewski. (2021) Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer’s Disease. International Journal of Molecular Sciences 22:15, pages 8142.
Crossref
Friedrich C. Luft. (2020) Solute excretion, metabolism, and cardio‐renoprotection via two distinct mechanisms revolutionize clinical outcomes. Acta Physiologica 232:3.
Crossref
Ursula Rauch-Kröhnert & Ulf Landmesser. (2021) Gliflozine – in Zukunft Kardioprotektiva?Gliflozins—in future cardioprotective drugs?. Der Internist 62:7, pages 786-795.
Crossref
Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Masayoshi Shirakawa, Edward A. O'Neill, Samuel S. Engel & Keith D. Kaufman. (2021) A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin . Diabetes, Obesity and Metabolism 23:6, pages 1342-1350.
Crossref
Rui Hu & Anita Layton. (2021) A Computational Model of Kidney Function in a Patient with Diabetes. International Journal of Molecular Sciences 22:11, pages 5819.
Crossref
Qian Chen, Ting Cao, NaNa Li, Cuirong Zeng, Shuangyang Zhang, Xiangxin Wu, Bikui Zhang & Hualin Cai. (2021) Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders. Frontiers in Pharmacology 12.
Crossref
Rishabh A. Babel & Manoj P. Dandekar. (2021) A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications. Current Diabetes Reviews 17:4, pages 457-473.
Crossref
Amir Fathi, Keeran Vickneson & Jagdeep S. Singh. (2020) SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Failure Reviews 26:3, pages 623-642.
Crossref
Manar M. Elhassan, Amr M. Mahmoud, Maha A. Hegazy & Shereen Mowaka. (2021) Electrochemical Determination of Ipragliflozin in Pure Form and in Spiked Human Plasma on a Glassy Carbon Electrode. Journal of The Electrochemical Society 168:3, pages 036507.
Crossref
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee & Byung‐Wan Lee. (2020) Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial. Diabetes, Obesity and Metabolism 23:2, pages 609-618.
Crossref
Katherine R. Tuttle, Frank C. BrosiusIIIIII, Matthew A. Cavender, Paola Fioretto, Kevin J. Fowler, Hiddo J.L. Heerspink, Tom Manley, Darren K. McGuire, Mark E. Molitch, Amy K. Mottl, Leigh Perreault, Sylvia E. Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner & Vlado Perkovic. (2021) SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Diabetes 70:1, pages 1-16.
Crossref
Katherine R. Tuttle, Frank C. BrosiusIIIIII, Matthew A. Cavender, Paola Fioretto, Kevin J. Fowler, Hiddo J.L. Heerspink, Tom Manley, Darren K. McGuire, Mark E. Molitch, Amy K. Mottl, Leigh Perreault, Sylvia E. Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner & Vlado Perkovic. (2021) SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases 77:1, pages 94-109.
Crossref
Alexia Piperidou, Charalampos Loutradis & Pantelis Sarafidis. (2020) SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. Journal of Human Hypertension 35:1, pages 12-25.
Crossref
Bjad K. Almutairy, El-Sayed Khafagy, Ahmed Alalaiwe, Mohammed F. Aldawsari, Saad M. Alshahrani, Bader B. Alsulays, Abdullah S. Alshetaili, Sultan M. Alshehri & Mohamed H. Fayed. (2020) Enhancing the Poor Flow and Tableting Problems of High Drug-Loading Formulation of Canagliflozin Using Continuous Green Granulation Process and Design-of-Experiment Approach. Pharmaceuticals 13:12, pages 473.
Crossref
Carmen Hierro-Bujalance, Carmen Infante-Garcia, Angel del Marco, Marta Herrera, Maria Jose Carranza-Naval, Javier Suarez, Pilar Alves-Martinez, Simon Lubian-Lopez & Monica Garcia-Alloza. (2020) Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Alzheimer's Research & Therapy 12:1.
Crossref
Martin R. Cowie & Miles Fisher. (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology 17:12, pages 761-772.
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis & Pantelis Sarafidis. (2020) The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry 27:39, pages 6682-6702.
Crossref
Api Chewcharat, Narut Prasitlumkum, Charat Thongprayoon, Tarun Bathini, Juan Medaura, Saraschandra Vallabhajosyula & Wisit Cheungpasitporn. (2020) Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Medical Sciences 8:4, pages 47.
Crossref
Michał Wiciński, Eryk Wódkiewicz, Karol Górski, Maciej Walczak & Bartosz Malinowski. (2020) Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals 13:11, pages 379.
Crossref
Anirudh Manoj, Subham Das, Anu Kunnath Ramachandran, Angel T Alex & Alex Joseph. (2020) SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Medicinal Chemistry 12:21, pages 1961-1990.
Crossref
Kris Kumar, Babikir Kheiri, Timothy F. Simpson, Mohammed Osman & Hind Rahmouni. (2020) Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials. The American Journal of Medicine 133:11, pages e625-e630.
Crossref
A. F. Verbovoy, N. I. Verbovaya & Yu. A. Dolgikh. (2020) Symbiosis of cardiology and endocrinology. Meditsinskiy sovet = Medical Council:14, pages 80-89.
Crossref
Raffaele Napoli, Gloria Formoso, Salvatore Piro, Giovanni Targher, Agostino Consoli & Francesco Purrello. (2020) Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases 30:11, pages 1926-1936.
Crossref
Ju-Hyun Kim, Dong Kyun Kim, Won-Gu Choi, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song, Sangkyu Lee & Hye Suk Lee. (2020) In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes. Pharmaceutics 12:9, pages 865.
Crossref
Karen E. Elkind-Hirsch, Ericka Seidemann & Renee Harris. (2020) A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. American Journal of Obstetrics & Gynecology MFM 2:3, pages 100139.
Crossref
Markolf Hanefeld, Holger Fleischmann, Thorsten Siegmund & Jochen Seufert. (2020) Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Therapy 11:8, pages 1645-1666.
Crossref
Rohit Jain, Hassan Awal & Sabyasachi Sen. (2020) Using adult stem cells to monitor endothelial dysfunction in diabetes mellitus. Journal of Diabetes and its Complications 34:7, pages 107588.
Crossref
Idrisu Sanusi, Alexander Sarnowski, David Russell-Jones & Lui G. Forni. (2020) A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition. Journal of Critical Care 57, pages 19-22.
Crossref
Yinqiu Yang, Chenhe Zhao, Yangli Ye, Mingxiang Yu & Xinhua Qu. (2020) Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes. Frontiers in Endocrinology 11.
Crossref
Bo Deng, Vitaliy Kireev, Kristina Melentyeva, Igor Kovalenko & Oleksandr Pakhomov. (2020) Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation. Problems of Cryobiology and Cryomedicine 30:1, pages 034-046.
Crossref
Petar M. Seferović, Andrew J.S. Coats, Piotr Ponikowski, Gerasimos Filippatos, Martin Huelsmann, Pardeep S. Jhund, Marija M. Polovina, Michel Komajda, Jelena Seferović, Ibrahim Sari, Francesco Cosentino, Giuseppe Ambrosio, Marco Metra, Massimo Piepoli, Ovidiu Chioncel, Lars H. Lund, Thomas Thum, Rudolf A. De Boer, Wilfried Mullens, Yuri Lopatin, Maurizio Volterrani, Loreena Hill, Johann Bauersachs, Alexander Lyon, Mark C. Petrie, Stefan Anker & Giuseppe M.C. Rosano. (2020) European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. European Journal of Heart Failure 22:2, pages 196-213.
Crossref
Rajeev Chawla, SV Madhu, BM Makkar, Sujoy Ghosh, Banshi Saboo & Sanjay Kalra. (2020) RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism 24:1, pages 1.
Crossref
Ahmad Yehya & Archana Sadhu. (2020) Sodium–Glucose Cotransporter 2 Inhibitor–Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review. Clinical Diabetes 38:1, pages 112-116.
Crossref
Jelena P. Seferovic & Petar M. Seferovic. (2020) Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure. Cardiology 145:5, pages 321-323.
Crossref
Rajeev Chawla, S. V. Madhu, B. M. Makkar, Sujoy Ghosh, Banshi Saboo & Sanjay Kalra. (2020) RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. International Journal of Diabetes in Developing Countries 40:S1, pages 1-122.
Crossref
Mahesh Sreekantan Krishna & Karthika Bahulayan Arun. 2020. Plant-derived Bioactives. Plant-derived Bioactives 259 277 .
Kaoru SugimotoIchiro AbeMidori MinezakiYuichi TakashiKentaro OchiHideyuki FujiiHanako OhishiYuka YamaoTadachika KudoKenji OheMakiko AbeYasushi OhnishiTomohiro ShinagawaShigeaki MukoubaraKunihisa Kobayashi. (2019) Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus. Drug Discoveries & Therapeutics 13:6, pages 322-327.
Crossref
Ying Shen, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Lin Lu, Feng Hua Ding & Wei Feng Shen. (2019) Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. Cardiovascular Diabetology 18:1.
Crossref
Tatiana Yakovleva, Victor Sokolov, Lulu Chu, Weifeng Tang, Peter J. Greasley, Helena Peilot Sjögren, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton & Robert C. Penland. (2019) Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes, Obesity and Metabolism 21:12, pages 2684-2693.
Crossref
Yufen Xiao, Yu Hu & Jianzhong Du. (2019) Controlling blood sugar levels with a glycopolymersome. Materials Horizons 6:10, pages 2047-2055.
Crossref
Rubiya Khursheed, Sachin Kumar Singh, Sheetu Wadhwa, Bhupinder Kapoor, Monica Gulati, Rajan Kumar, Arya Kadukkattil Ramanunny, Ankit Awasthi & Kamal Dua. (2019) Treatment strategies against diabetes: Success so far and challenges ahead. European Journal of Pharmacology 862, pages 172625.
Crossref
Ban Liu, Yuliang Wang, Yangyang Zhang & Biao Yan. (2019) Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Current Topics in Medicinal Chemistry 19:20, pages 1818-1849.
Crossref
Shoji TakakuraToshiyuki Takasu. (2019) Acute and Direct Effects of Sodium–Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats. Biological and Pharmaceutical Bulletin 42:10, pages 1707-1712.
Crossref
Yuan‐Di Halvorsen, John P. Lock, Wenjiong Zhou, Fang Zhu & Mason W. Freeman. (2019) A 24‐week, randomized, double‐blind, active‐controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism 21:10, pages 2248-2256.
Crossref
Priyanka A. Shah, Pranav S. Shrivastav, Vinay Sharma & Manish S. Yadav. (2019) Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 175, pages 112790.
Crossref
Ying-Ying Chen, Tsung-Tien Wu, Chiu-Yi Ho, Tung-Chen Yeh, Gwo-Ching Sun, Ya-Hsin Kung, Tzyy-Yue Wong, Ching-Jiunn Tseng & Pei-Wen Cheng. (2019) Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus. International Journal of Molecular Sciences 20:18, pages 4357.
Crossref
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara & Kohei Kaku. (2019) Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT). Journal of Diabetes Investigation 10:5, pages 1272-1283.
Crossref
Toshiyuki Takasu & Shoji Takakura. (2019) Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. Life Sciences 230, pages 19-27.
Crossref
Niki Katsiki, George Dimitriadis, George Hahalis, Nikolaos Papanas, Nikolaos Tentolouris, Filippos Triposkiadis, Vasilios Tsimihodimos, Costas Tsioufis, Dimitri P. Mikhailidis & Christos Mantzoros. (2019) Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism 96, pages 92-100.
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis & Pantelis Sarafidis. (2019) The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry 11:11, pages 1285-1303.
Crossref
Ze Chen & Gerui Li. (2019) Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation 39:6, pages 521-531.
Crossref
Leonardo Pozo, Fatimah Bello, Andres Suarez, Francisco E Ochoa-Martinez, Yamely Mendez, Chelsea H Chang & Salim Surani. (2019) Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. World Journal of Diabetes 10:5, pages 291-303.
Crossref
Yoshimasa Aso, Kanako Kato, Shintaro Sakurai, Haruka Kishi, Masanori Shimizu, Teruo Jojima, Toshie Iijima, Yuko Maejima, Kenju Shimomura & Isao Usui. (2019) Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease. International Journal of Clinical Practice 73:5, pages e13335.
Crossref
Ting-I Lee, Yao-Chang Chen, Yung-Kuo Lin, Cheng-Chih Chung, Yen-Yu Lu, Yu-Hsun Kao & Yi-Jen Chen. (2019) Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats. International Journal of Molecular Sciences 20:7, pages 1680.
Crossref
Awadhesh Kumar Singh, Ambika G. Unnikrishnan, Abdul H. Zargar, Ajay Kumar, Ashok K. Das, Banshi Saboo, Binayak Sinha, Kalyan Kumar Gangopadhyay, Pradeep G. Talwalkar, Samit Ghosal, Sanjay Kalra, Shashank Joshi, Surendra Kumar Sharma, Usha Sriram & Viswanathan Mohan. (2019) Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Therapy 10:2, pages 393-428.
Crossref
Shoji Takakura & Toshiyuki Takasu. (2019) First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats. Clinical and Experimental Pharmacology and Physiology 46:3, pages 266-273.
Crossref
Hong Shen, Renato J. Scialis & Lois Lehman-McKeeman. (2019) Xenobiotic Transporters in the Kidney: Function and Role in Toxicity. Seminars in Nephrology 39:2, pages 159-175.
Crossref
Nataša Vidić & Aleksandar Đenić. (2019) Inhibitor natrijum-glukoznog kotransportera tipa 2 - dapagliflozin u terapiji obolelih od diabetes mellitus tipa 2. Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma 24:74, pages 29-39.
Crossref
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit & Guillermo E. Umpierrez. (2019) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. Endocrine Practice 25:1, pages 69-101.
Crossref
Cheng Hu & Weiping Jia. (2019) Therapeutic medications against diabetes: What we have and what we expect. Advanced Drug Delivery Reviews 139, pages 3-15.
Crossref
John Wilding, Thomas Godec, Kamlesh Khunti, Stuart Pocock, Robin Fox, Liam Smeeth, Per Clauson, Peter Fenici, Niklas Hammar & Jesús Medina. (2018) Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Medicine 16:1.
Crossref
Joseph E. Cruz, Tania Ahuja & Mary Barna Bridgeman. (2018) Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Annals of Pharmacotherapy 52:12, pages 1238-1249.
Crossref
A.K. Pancholia. (2018) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart Journal 70:6, pages 915-921.
Crossref
Kajal GC, Myriam Jean Cadet, Shabeena Hirani & Tisha Thomas. (2018) Type 2 diabetes management. The Nurse Practitioner 43:10, pages 40-47.
Crossref
Robyn L. Houlden, Joy L. Yen & Sarah Moore. (2018) Effectiveness of an Interprofessional Glycemic Optimization Clinic on Preoperative Glycated Hemoglobin Levels for Adult Patients With Type 2 Diabetes Undergoing Bariatric Surgery. Canadian Journal of Diabetes 42:5, pages 514-519.
Crossref
İrfan Karahan, Çağar Alp & Aşkın Güngüneş. (2018) Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment. Ortadoğu Tıp Dergisi 10:3, pages 381-385.
Crossref
Natalia de Albuquerque Rocha, Ian J Neeland, Peter A McCullough, Robert D Toto & Darren K McGuire. (2018) Effects of sodium glucose co-transporter 2 inhibitors on the kidney. Diabetes and Vascular Disease Research 15:5, pages 375-386.
Crossref
Yi-Hsin Lin. (2018) Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors. Journal of the Formosan Medical Association 117:9, pages 849-854.
Crossref
Yun Kyung Cho, Ye-Jee Kim, Yu Mi Kang, Seung Eun Lee, Joong-Yeol Park, Woo Je Lee & Chang Hee Jung. (2018) Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis. Journal of Diabetes Investigation 9:4, pages 882-892.
Crossref
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang & Dayong Zhang. (2018) Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents. Future Medicinal Chemistry 10:10, pages 1261-1276.
Crossref
Richard E. Pratley, Roy Eldor, Annaswamy Raji, Gregory Golm, Susan B. Huyck, Yanping Qiu, Sheila Sunga, Jeremy Johnson, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2018) Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial . Diabetes, Obesity and Metabolism 20:5, pages 1111-1120.
Crossref
Muhammad Maqbool, Mark E. Cooper & Karin A.M. Jandeleit-Dahm. (2018) Cardiovascular Disease and Diabetic Kidney Disease. Seminars in Nephrology 38:3, pages 217-232.
Crossref
Anderson R. Aguillón, Alessandra Mascarello, Natanael D. Segretti, Hatylas F. Z de Azevedo, Cristiano R. W. Guimaraes, Leandro S. M. Miranda & Rodrigo O. M. A. de Souza. (2018) Synthetic Strategies toward SGLT2 Inhibitors. Organic Process Research & Development 22:4, pages 467-488.
Crossref
Jenny E. Blau, Viviana Bauman, Ellen M. Conway, Paolo Piaggi, Mary F. Walter, Elizabeth C. Wright, Shanna Bernstein, Amber B. Courville, Michael T. Collins, Kristina I. Rother & Simeon I. Taylor. (2018) Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3:8.
Crossref
Sean Wharton, Sue D. Pedersen, David C.W. Lau & Arya M. Sharma. (2018) Weight Management in Diabetes. Canadian Journal of Diabetes 42, pages S124-S129.
Crossref
Yunona Khomitskaya, Nadezhda Tikhonova, Konstantin Gudkov, Svetlana Erofeeva, Victoria Holmes, Brian Dayton, Nigel Davies, David W. Boulton & Weifeng Tang. (2018) Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects. Clinical Therapeutics 40:4, pages 550-561.e3.
Crossref
Se Hee Min, Jeong-Hwa Yoon, Sun Joon Moon, Seokyung Hahn & Young Min Cho. (2018) Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Scientific Reports 8:1.
Crossref
Takeshi Osonoi, Shinya Nakamoto, Miyoko Saito, Atsuko Tamasawa, Hidenori Ishida & Yusuke Osonoi. (2018) Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics. Journal of Diabetes Investigation 9:2, pages 341-353.
Crossref
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Darcy Hille, Yuqin Liao, Susan Huyck, Gregory Golm, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2018) Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes, Obesity and Metabolism 20:3, pages 530-540.
Crossref
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring & Steven G. Terra. (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes, Obesity and Metabolism 20:3, pages 520-529.
Crossref
James Pavela, Rahul Suresh, Rebecca S. Blue, Charles H. Mathers & L. Maria Belalcazar. (2018) Management of Diabetes During Air Travel: A Systematic Literature Review of Current Recommendations and their Supporting Evidence. Endocrine Practice 24:2, pages 205-219.
Crossref
Michael d'Emden, John Amerena, Gary Deed, Carol Pollock & Mark E. Cooper. (2018) SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. Diabetes Research and Clinical Practice 136, pages 23-31.
Crossref
Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2017) Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Therapy 9:1, pages 193-207.
Crossref
Weidong Shang, Ze-Dong Mou, Hua Tang, Xia Zhang, Jie Liu, Zhengyan Fu & Dawen Niu. (2018) Site-Selective O-Arylation of Glycosides. Angewandte Chemie International Edition 57:1, pages 314-318.
Crossref
Weidong Shang, Ze-Dong Mou, Hua Tang, Xia Zhang, Jie Liu, Zhengyan Fu & Dawen Niu. (2018) Site-Selective O-Arylation of Glycosides. Angewandte Chemie 130:1, pages 320-324.
Crossref
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit & Guillermo E. Umpierrez. (2018) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice 24:1, pages 91-121.
Crossref
Michael E. Røder. (2017) Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. Therapeutic Advances in Chronic Disease 9:1, pages 33-50.
Crossref
Natalia A. Rocha & Peter A. McCullough. (2018) Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. Kidney International Supplements 8:1, pages 8-17.
Crossref
Alexandros Briasoulis, Omar Al Dhaybi & George L. Bakris. (2018) SGLT2 Inhibitors and Mechanisms of Hypertension. Current Cardiology Reports 20:1.
Crossref
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment 527 569 .
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment 1 44 .
Y. S. Khalimov, P. V. Agafonov & V. G. Kuzmich. (2017) ROLE AND PLACE OF DAPAGLIFLOZIN IN THE MANAGEMENT OF 2nd TYPE DIABETES: FROM THEORY TO PRACTICE. Medical Council:3, pages 22-30.
Crossref
Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn & Seung-Hyun Ko. (2017) A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids in Health and Disease 16:1.
Crossref
Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Kayoko Ikehara, Eiichiro Kanda, Hiroshi Uchino & Takahisa Hirose. (2017) Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovascular Diabetology 16:1.
Crossref
Honghong Zou, Baoqin Zhou & Gaosi Xu. (2017) SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovascular Diabetology 16:1.
Crossref
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito & Tsutomu Hirano. (2017) Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovascular Diabetology 16:1.
Crossref
Alexander J.M. Brown, Chim Lang, Rory McCrimmon & Allan Struthers. (2017) Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovascular Disorders 17:1.
Crossref
G.P. Fadini, G. Zatti, A. Consoli, E. Bonora, G. Sesti, A. Avogaro, A. Consoli, G. Formoso, D. Antenucci, G. Grossi, A. Pucci, G. Sesti, F. Andreozzi, L. Indrieri, G. Capobianco, A. Gatti, R. Bonadonna, I. Zavaroni, A. Dei Cas, G. Felace, P. Li Volsi, R. Buzzetti, G. Leto, F. D'Angelo, S. Morano, A. Giaccari, G. Sorice, E. Orsi, A. Carlo Bossi, F. Querci, E. Duratorre, C. Malagola, I. Franzetti, P. Silvia Morpurgo, M. Boemi, M. Petrelli, G. Aimaretti, I. Karamouzis, F. Cavalot, G. Saglietti, G. Gruden, E. Devangelio, G. Cazzetta, O. Lamacchia, S. Cervone, L. Frittitta, S. Arena, A. Di Benedetto, S. Piro, C. Giordano, M. Rizzo, R. Chianetta, C. Mannina, A. Solini, A. Natali, R. Anichini, F. Dotta, B. Fattor, A. Avogaro, G.P. Fadini, E. Bonora, M. Cigolini, N. Simioni, V. Frison, M. Poli, A. Lapolla, N. Cristiano Chilelli & C. Vinci. (2017) Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases 27:12, pages 1089-1097.
Crossref
Luca Di Lullo, Michela Mangano, Claudio Ronco, Vincenzo Barbera, Antonio De Pascalis, Antonio Bellasi, Domenico Russo, Biagio Di Iorio & Mario Cozzolino. (2017) The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S295-S305.
Crossref
Jaime Davidson, Sanjay Kalra, Vikram Singh, Mayuresh Fegade, Gursimran Singh & Amey Mane. (2017) Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S159-S168.
Crossref
Javed Butler, Carine E. Hamo, Gerasimos Filippatos, Stuart J. Pocock, Richard A. Bernstein, Martina Brueckmann, Alfred K. Cheung, Jyothis T. George, Jennifer B. Green, James L. Januzzi, Sanjay Kaul, Carolyn S.P. Lam, Gregory Y.H. Lip, Nikolaus Marx, Peter A. McCullough, Cyrus R. Mehta, Piotr Ponikowski, Julio Rosenstock, Naveed Sattar, Afshin Salsali, Benjamin M. Scirica, Sanjiv J. Shah, Hiroyuki Tsutsui, Subodh Verma, Christoph Wanner, Hans-Juergan Woerle, Faiez Zannad & Stefan D. Anker. (2017) The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. European Journal of Heart Failure 19:11, pages 1390-1400.
Crossref
Lucia M. Novak & Davida F. Kruger. (2017) Bolstering your armamentarium with SGLT2 inhibitors. The Nurse Practitioner 42:10, pages 28-34.
Crossref
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji & Kohei Kaku. (2017) Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes, Obesity and Metabolism 19:10, pages 1397-1407.
Crossref
A. Jamieson & N. Finer. (2017) Can we reconcile ‘the obesity paradox’ with recent cardiovascular outcome trials in diabetes?. Clinical Obesity 7:5, pages 255-259.
Crossref
Krit Jaikumkao, Anchalee Pongchaidecha, Varanuj Chatsudthipong, Siriporn C. Chattipakorn, Nipon Chattipakorn & Anusorn Lungkaphin. (2017) The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. Biomedicine & Pharmacotherapy 94, pages 176-187.
Crossref
Tohru Hira, Toshiki Koga, Kazuyo Sasaki & Hiroshi Hara. (2017) Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet. Biochemical and Biophysical Research Communications 492:2, pages 161-165.
Crossref
Fernando Gomez-Peralta, Cristina Abreu, Albert Lecube, Diego Bellido, Alfonso Soto, Cristóbal Morales, Miguel Brito-Sanfiel & Guillermo Umpierrez. (2017) Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes. Diabetes Therapy 8:5, pages 953-962.
Crossref
Daniel Wolverton & Melissa M. Blair. (2017) Fracture risk associated with common medications used in treating type 2 diabetes mellitus. American Journal of Health-System Pharmacy 74:15, pages 1143-1151.
Crossref
Wenying Yang, Linong Ji, Zhiguang Zhou, Valerie A. Cain, Kristina M. Johnsson & C. David Sjöström. (2017) Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis. Journal of Diabetes 9:8, pages 787-799.
Crossref
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura & Eiji Kurosaki. (2017) Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice. European Journal of Pharmacology 809, pages 163-171.
Crossref
Joshua A. Levine, Susan L. Karam & Grazia Aleppo. (2017) SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns. Current Diabetes Reports 17:7.
Crossref
Robert R. Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu & Lars Hansen. (2017) Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study . Diabetes, Obesity and Metabolism 19:6, pages 814-821.
Crossref
M. Dolores García de Lucas & Julián Olalla. (2017) Experience of using ISGTL-2 in patients with DM2 and HIV infection. European Journal of Internal Medicine 41, pages e29.
Crossref
Victor Rusu, Eitan Hoch, Josep M. Mercader, Danielle E. Tenen, Melissa Gymrek, Christina R. Hartigan, Michael DeRan, Marcin von Grotthuss, Pierre Fontanillas, Alexandra Spooner, Gaelen Guzman, Amy A. Deik, Kerry A. Pierce, Courtney Dennis, Clary B. Clish, Steven A. Carr, Bridget K. Wagner, Monica Schenone, Maggie C.Y. Ng, Brian H. Chen, Federico Centeno-Cruz, Carlos Zerrweck, Lorena Orozco, David M. Altshuler, Stuart L. Schreiber, Jose C. Florez, Suzanne B.R. Jacobs, Eric S. Lander, Maggie C.Y. Ng, Daniel Shriner, Brian H. Chen, Jiang Li, Wei-Min Chen, Xiuqing Guo, Jiankang Liu, Suzette J. Bielinski, Lisa R. Yanek, Michael A. Nalls, Mary E. Comeau, Laura J. Rasmussen-Torvik, Richard A. Jensen, Daniel S. Evans, Yan V. Sun, Ping An, Sanjay R. Patel, Yingchang Lu, Jirong Long, Loren L. Armstrong, Lynne Wagenknecht, Lingyao Yang, Beverly M. Snively, Nicholette D. Palmer, Poorva Mudgal, Carl D. Langefeld, Keith L. Keene, Barry I. Freedman, Josyf C. Mychaleckyj, Uma Nayak, Leslie J. Raffel, Mark O. Goodarzi, Y-D Ida Chen, Herman A. TaylorJr.Jr., Adolfo Correa, Mario Sims, David Couper, James S. Pankow, Eric Boerwinkle, Adebowale Adeyemo, Ayo Doumatey, Guanjie Chen, Rasika A. Mathias, Dhananjay Vaidya, Andrew B. Singleton, Alan B. Zonderman, Robert P. IgoJr.Jr., John R. Sedor, Edmond K. Kabagambe, David S. Siscovick, Barbara McKnight, Kenneth Rice, Yongmei Liu, Wen-Chi Hsueh, Wei Zhao, Lawrence F. Bielak, Aldi Kraja, Michael A. Province, Erwin P. Bottinger, Omri Gottesman, Qiuyin Cai, Wei Zheng, William J. Blot, William L. Lowe, Jennifer A. Pacheco, Dana C. Crawford, Elin Grundberg, Stephen S. Rich, M. Geoffrey Hayes, Xiao-Ou Shu, Ruth J.F. Loos, Ingrid B. Borecki, Patricia A. Peyser, Steven R. Cummings, Bruce M. Psaty, Myriam Fornage, Sudha K. Iyengar, Michele K. Evans, Diane M. Becker, W.H. Linda Kao, James G. Wilson, Jerome I. Rotter, Michèle M. Sale, Simin Liu, Charles N. Rotimi, Donald W. Bowden, Josep M. Mercader, Alicia Huerta-Chagoya, Humberto García-Ortiz, Hortensia Moreno-Macías, Alisa Manning, Lizz Caulkins, Noël P. Burtt, Jason Flannick, Nick Patterson, Carlos A. Aguilar-Salinas, Teresa Tusié-Luna, David Altshuler, Jose C. Florez, Angélica Martínez-Hernández, Federico Centeno-Cruz, Francisco Martin Barajas-Olmos, Carlos Zerrweck, Cecilia Contreras-Cubas, Elvia Mendoza-Caamal, Cristina Revilla-Monsalve, Sergio Islas-Andrade, Emilio Córdova, Xavier Soberón, Lorena Orozco, Clicerio González-Villalpando, María Elena González-Villalpando, Christopher A. Haiman, Lynne Wilkens, Loic Le Marchand, Kristine Monroe, Laurence Kolonel, Olimpia Arellano-Campos, Maria L. Ordóñez-Sánchez, Maribel Rodríguez-Torres, Yayoi Segura-Kato, Rosario Rodríguez-Guillén, Ivette Cruz-Bautista, Linda Liliana Muñoz-Hernandez, Tamara Sáenz, Donají Gómez, Ulices Alvirde, Paloma Almeda-Valdés & Maria L. Cortes. (2017) Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms. Cell 170:1, pages 199-212.e20.
Crossref
Ashley M. Zurek, Raghunandan Yendapally & Elizabeth M. Urteaga. (2017) A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis. Diabetes Spectrum 30:2, pages 137-142.
Crossref
Steven G. Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring & Sam Dagogo-Jack. (2017) Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes, Obesity and Metabolism 19:5, pages 721-728.
Crossref
Mariyana Hristova. (2017) Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory. Medical Hypotheses 102, pages 61-64.
Crossref
Jean-Luc Faillie. (2017) Pharmacological aspects of the safety of gliflozins. Pharmacological Research 118, pages 71-81.
Crossref
Jiyoung Park & Hyeung-Jin Jang. (2017) Anti-diabetic effects of natural products an overview of therapeutic strategies. Molecular & Cellular Toxicology 13:1, pages 1-20.
Crossref
Éva Bokor, Sándor Kun, David Goyard, Marietta Tóth, Jean-Pierre Praly, Sébastien Vidal & László Somsák. (2017) C -Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential . Chemical Reviews 117:3, pages 1687-1764.
Crossref
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit & Guillermo E. Umpierrez. (2017) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. Endocrine Practice 23:2, pages 207-238.
Crossref
Hermann Koepsell. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & Therapeutics 170, pages 148-165.
Crossref
Clifford J. Bailey. 2017. Textbook of Diabetes. Textbook of Diabetes 1000 1011 .
Sara Dominijanni, Silvia Cipriani, Moreno Malaguti, Luigi Triolo, Ferruccio Ansali & Fulvio Floccari. (2017) Antidiabetic Medication in Patients with Chronic Kidney Disease: What's New?. Nephrology @ Point of Care 3:1, pages napoc.5000210.
Crossref
Manoja K. BrahmaMark E. PepinAdam R. Wende. (2017) My Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy. Diabetes & Metabolism Journal 41:1, pages 1.
Crossref
Fumiaki Obata, Kenji Tani, Harutaka Yamaguchi, Ryo Tabata, Hiroyasu Bando & Issei Imoto. (2017) Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial. The Journal of Medical Investigation 64:1.2, pages 50-57.
Crossref
Miles Fisher & Gerard McKayGerard McKay & Rachel Livingstone. 2017. Essentials of SGLT2 Inhibitors in Diabetes. Essentials of SGLT2 Inhibitors in Diabetes 13 35 .
Patricia Freitas Corradi, Nidhi Agrawal, Namrata Gumaste & Ira J. Goldberg. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus 533 550 .
Jagdeep S. S. Singh, Amir Fathi, Keeran Vickneson, Ify Mordi, Mohapradeep Mohan, J. Graeme Houston, Ewan R. Pearson, Allan D. Struthers & Chim C. Lang. (2016) Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovascular Diabetology 15:1.
Crossref
Atsushi Tanaka, Teruo Inoue, Masafumi Kitakaze, Jun-ichi Oyama, Masataka Sata, Isao Taguchi, Wataru Shimizu, Hirotaka Watada, Hirofumi Tomiyama, Junya Ako, Yasushi Sakata, Toshihisa Anzai, Masaaki Uematsu, Makoto Suzuki, Kazuo Eguchi, Akira Yamashina, Yoshihiko Saito, Yasunori Sato, Shinichiro Ueda, Toyoaki Murohara & Koichi Node. (2016) Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovascular Diabetology 15:1.
Crossref
Angeliki M. Stamatouli & Silvio E. Inzucchi. (2016) Implications of the EMPA-REG Trial for Clinical Care and Research. Current Diabetes Reports 16:12.
Crossref
Nikolaus Marx & Darren K. McGuire. (2016) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. European Heart Journal 37:42, pages 3192-3200.
Crossref
S. Matthaei, N. Aggarwal, P. Garcia-Hernandez, N. Iqbal, H. Chen, E. Johnsson, A. Chin & L. Hansen. (2016) One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes, Obesity and Metabolism 18:11, pages 1128-1133.
Crossref
Wenying Yang, Ping Han, Kyung-Wan Min, Bei Wang, Traci Mansfield, Caroline T'Joen, Nayyar Iqbal, Eva Johnsson & Agata Ptaszynska. (2016) Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. Journal of Diabetes 8:6, pages 796-808.
Crossref
Baptist Gallwitz. (2016) So bekommen Sie den Blutzucker bei Typ-2-Diabetes in den GriffTherapy with oral antidiabetic drugs. MMW - Fortschritte der Medizin 158:S3, pages 48-54.
Crossref
F.J. Ampudia-Blasco & E. Perelló Camacho. (2016) Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insulínicos. Medicine - Programa de Formación Médica Continuada Acreditado 12:18, pages 1013-1025.
Crossref
André J. Scheen. (2016) SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports 16:10.
Crossref
Wing Chow, Gavin Miyasato, Fotios K. Kokkotos, Robert A. Bailey, Erin K. Buysman & Henry J. Henk. (2016) Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus—A Multi-Database Synthesis. Clinical Therapeutics 38:9, pages 2071-2082.
Crossref
Sanjay Kalra, Vikram Singh & Dinesh Nagrale. (2016) Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Advances in Therapy 33:9, pages 1502-1518.
Crossref

Displaying 200 of 232 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.